Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMTT Regimen for First-line PCNS DLBCL
NCT06832267Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, methotrexate, temozolomide, thiotepa in primary central nervous system lymphoma (PCNSL), sponsored by Zhejiang Cancer Hospital. Started Feb 2025; status: recruiting.
02
Drugs
rituximabmethotrexatetemozolomidethiotepa
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT06832267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832267.